Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 289

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells

Rech, Andrew J., Vonderheide, Robert H.·2009·Annals of the New York Academy of Sciences

Abstract

CD4+ regulatory T cells frustrate productive tumor immune surveillance and represent an obstacle for cancer immunotherapy. In mice, anti‐CD25 antibody is an effective method of depleting CD25+ FOXP3+ T regulatory cells (Tregs) in vivo and enhancing cancer immunity. Here, we propose the use of the anti‐CD25 monoclonal antibody daclizumab for the depletion of Tregs in cancer patients. In early results from an ongoing clinical trial, a single intravenous infusion of daclizumab in patients with metastatic breast cancer is associated with a marked and prolonged elimination of CD25+ FOXP3+ Tregs in peripheral blood. When a cancer antigen peptide vaccine is administered during the daclizumab‐induced Treg nadir, effective generation of cytotoxic T lymphocytes has been observed, including those specific for neo‐antigens, such as cytomegalovirus peptide used as an immunological control. If confirmed in additional patients, these observations suggest that daclizumab may be an effective and available therapeutic agent for Treg modulation in patients with cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1749-6632.2009.04939.x

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 289

Metadata

Authors
Rech, A. J., & Vonderheide, R. H.
Venue
Annals of the New York Academy of Sciences
Publisher
Wiley
Published
2009-09
Volume
1174
Issue
1
Pages
99-106
ISSN
  • 0077-8923 (ISSN-L)
  • 1749-6632
OpenAlex
W2060656939
Cited by
289
References
44
FWCI
13.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells. https://app.cochat.ai/papers/10.1111/j.1749-6632.2009.04939.x
The paper
Rech, A. J., & Vonderheide, R. H. (2009). Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2009.04939.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.